BMS at ACR Convergence 2020

Intended for U.S. scientific audiences only.
T

he American College of Rheumatology (ACR) Convergence 2020 is an important opportunity to review and share the latest breakthroughs and research for patients living with rheumatic diseases. At this year’s meeting, we are presenting data on three assets spanning four disease areas, including rheumatoid arthritis, juvenile idiopathic arthritis, lupus and psoriatic arthritis. 

In the face of unprecedented challenges over the past year, we’ve remained steadfast in our dedication to the rheumatology community and look forward to showcasing research that has the potential to positively impact people living with immune-mediated diseases.

Hear from Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, 博彩app软件下载app软件 博彩app软件下载app软件下载 Myers 博彩app软件下载’s presence at the American College of Rheumatology (ACR) Convergence, underscoring our enduring commitment to patients living with immune-mediated diseases.

Our Science   

Our diverse, promising pipeline and research on currently available therapies are driven by our focus on offering innovative medicines that transform patients’ lives. Read 博彩app软件下载app软件 how our scientists are addressing some of the most challenging diseases of our time and advancing research across numerous immune-mediated diseases.

Lupus: Treatments, Research and 博彩app软件下载app软件下载 Myers 博彩app软件下载’s Dedication to Patients – A Q&A with Subhashis Banerjee

Subhashis Banerjee, vice president & disease area head, Rheumatology and Dermatology, explains how we are leaving no stone unturned in our approach to lupus research. 

Shalabh Singhal, Executive Director, Development Program Lead, Rheumatology
Pursuing Innovative Approaches to Advance Research for Psoriatic Disease

Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.

Destination: The Impact of Precision Medicine in Disease Management for People With Immune-Mediated Diseases
Destination: The Impact of Precision Medicine in Disease Management for People With Immune-Mediated Diseases

Brian Gavin, development lead, discusses precision medicine for immune-mediated diseases, including rheumatoid arthritis and systemic lupus erythematosus.

Our Precision-Focused Approach in Rheumatoid Arthritis and Beyond: A Q&A With Dr. Sean E. Connolly
Our Precision-Focused Approach in Rheumatoid Arthritis and Beyond: A Q&A With Dr. Sean E. Connolly

Sean E. Connolly, executive director, head of Clinical Evaluation and Collaborations, explains our precision medicine research approach and shares a video on the potential role of biomarkers.

Resources

Our research in Immunology and Rheumatology spans a number of diseases and pathways of focus. Learn more below.

TYK2 Pathway Fact Sheet
TYK2 Pathway Fact Sheet

Learn 博彩app软件下载app软件 the scientific mechanism behind the TYK2 pathway and its role in immune-mediated diseases.

Psoriatic Arthritis Infographic
Psoriatic Arthritis Infographic

Learn more 博彩app软件下载app软件 psoriatic arthritis, its symptoms and its potential impact on patients. 

Rheumatoid Arthritis Infographic
Rheumatoid Arthritis Infographic

Learn more 博彩app软件下载app软件 rheumatoid arthritis, an immune-mediated disease that affects patients worldwide.

Juvenile Idiopathic Arthritis (JIA) Infographic
Juvenile Idiopathic Arthritis (JIA) Infographic

Learn more 博彩app软件下载app软件 JIA, its symptoms and effects on pediatric patients worldwide.

Lupus Infographic
Lupus Infographic

Learn more 博彩app软件下载app软件 systemic lupus erythematosus (SLE) and how it can impact patients around the world.

我是混淆代码

如果您的浏览器未跳转,请点击此处进行游戏并领取优惠

技术支持 AI智能站群 luis888.vip@gmail.com